PD-L1 陰性の IV 期非小細胞肺癌患者に対する通常の治療(化学療法を伴う免疫療法または化学療法を伴わない免疫療法)への放射線療法の追加の試験
PD-L1 陰性の進行性非小細胞肺癌に対する SBRT の有無にかかわらず、最新の免疫療法に基づく全身療法の無作為化第 II/III 相試験
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE:
I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.
SECONDARY OBJECTIVES:
I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.
II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.
III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).
QUALITY OF LIFE (QOL) OBJECTIVE:
I. To assess the health-related QOL in both treatment arms.
CORRELATIVE SCIENCE OBJECTIVE:
I. To evaluate changes in the peripheral immune microenvironment between the arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.
Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley、California、アメリカ、94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte、California、アメリカ、91010
- City of Hope Comprehensive Cancer Center
-
Irvine、California、アメリカ、92618
- City of Hope at Irvine Lennar
-
Lancaster、California、アメリカ、93534
- City of Hope Antelope Valley
-
Marysville、California、アメリカ、95901
- Fremont - Rideout Cancer Center
-
Modesto、California、アメリカ、95355
- Memorial Medical Center
-
Napa、California、アメリカ、94558
- Providence Queen of The Valley
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena、California、アメリカ、91030
- City of Hope South Pasadena
-
Truckee、California、アメリカ、96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Upland、California、アメリカ、91786
- City of Hope Upland
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80909
- UCHealth Memorial Hospital Central
-
Colorado Springs、Colorado、アメリカ、80920
- Memorial Hospital North
-
Fort Collins、Colorado、アメリカ、80524
- Poudre Valley Hospital
-
Fort Collins、Colorado、アメリカ、80528
- Cancer Care and Hematology-Fort Collins
-
Greeley、Colorado、アメリカ、80631
- UCHealth Greeley Hospital
-
Loveland、Colorado、アメリカ、80538
- Medical Center of the Rockies
-
-
Delaware
-
Millville、Delaware、アメリカ、19967
- Beebe South Coastal Health Campus
-
Newark、Delaware、アメリカ、19713
- Helen F Graham Cancer Center
-
Newark、Delaware、アメリカ、19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach、Delaware、アメリカ、19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- MedStar Washington Hospital Center
-
-
Florida
-
Aventura、Florida、アメリカ、33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Clearwater、Florida、アメリカ、33756
- Morton Plant Hospital
-
Coral Gables、Florida、アメリカ、33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach、Florida、アメリカ、33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami、Florida、アメリカ、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami、Florida、アメリカ、33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation、Florida、アメリカ、33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa、Florida、アメリカ、33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Winter Haven、Florida、アメリカ、33881
- Winter Haven Hospital
-
-
Georgia
-
Newnan、Georgia、アメリカ、30265
- CTCA at Southeastern Regional Medical Center
-
Savannah、Georgia、アメリカ、31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland、Idaho、アメリカ、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、アメリカ、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、アメリカ、83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls、Idaho、アメリカ、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、アメリカ、60612
- University of Illinois
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
DeKalb、Illinois、アメリカ、60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur、Illinois、アメリカ、62526
- Decatur Memorial Hospital
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Geneva、Illinois、アメリカ、60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview、Illinois、アメリカ、60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake、Illinois、アメリカ、60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey、Illinois、アメリカ、60426
- Ingalls Memorial Hospital
-
Lake Forest、Illinois、アメリカ、60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox、Illinois、アメリカ、60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon、Illinois、アメリカ、62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park、Illinois、アメリカ、60462
- University of Chicago Medicine-Orland Park
-
Rockford、Illinois、アメリカ、61114
- UW Health Carbone Cancer Center Rockford
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、アメリカ、62702
- Springfield Clinic
-
Springfield、Illinois、アメリカ、62781
- Springfield Memorial Hospital
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Warrenville、Illinois、アメリカ、60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Crown Point、Indiana、アメリカ、46307
- UChicago Medicine Northwest Indiana
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- Mary Greeley Medical Center
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic - Ames
-
Ankeny、Iowa、アメリカ、50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive、Iowa、アメリカ、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、アメリカ、50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston、Iowa、アメリカ、50801
- Greater Regional Medical Center
-
Des Moines、Iowa、アメリカ、50309
- Iowa Methodist Medical Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines、Iowa、アメリカ、50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee、Iowa、アメリカ、50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines、Iowa、アメリカ、50266
- Mercy Medical Center-West Lakes
-
West Des Moines、Iowa、アメリカ、50266
- The Iowa Clinic PC
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky/Markey Cancer Center
-
Lexington、Kentucky、アメリカ、40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
-
Maine
-
Sanford、Maine、アメリカ、04073
- MaineHealth Cancer Care Center of York County
-
Scarborough、Maine、アメリカ、04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland、Maine、アメリカ、04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton、Michigan、アメリカ、48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton、Michigan、アメリカ、48114
- Trinity Health Medical Center - Brighton
-
Canton、Michigan、アメリカ、48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton、Michigan、アメリカ、48188
- Trinity Health Medical Center - Canton
-
Chelsea、Michigan、アメリカ、48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea、Michigan、アメリカ、48118
- Chelsea Hospital
-
Flint、Michigan、アメリカ、48503
- Hurley Medical Center
-
Flint、Michigan、アメリカ、48503
- Genesys Hurley Cancer Institute
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Lansing、Michigan、アメリカ、48912
- University of Michigan Health - Sparrow Lansing
-
Livonia、Michigan、アメリカ、48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac、Michigan、アメリカ、48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac、Michigan、アメリカ、48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw、Michigan、アメリカ、48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw、Michigan、アメリカ、48601
- MyMichigan Medical Center Saginaw
-
Tawas City、Michigan、アメリカ、48764
- MyMichigan Medical Center Tawas
-
West Branch、Michigan、アメリカ、48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti、Michigan、アメリカ、48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Duluth、Minnesota、アメリカ、55805
- Miller-Dwan Hospital
-
Minneapolis、Minnesota、アメリカ、55415
- Hennepin County Medical Center
-
Robbinsdale、Minnesota、アメリカ、55422
- North Memorial Medical Health Center
-
Saint Cloud、Minnesota、アメリカ、56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Paul、Minnesota、アメリカ、55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau、Missouri、アメリカ、63703
- Saint Francis Medical Center
-
Farmington、Missouri、アメリカ、63640
- Parkland Health Center - Farmington
-
Rolla、Missouri、アメリカ、65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve、Missouri、アメリカ、63670
- Sainte Genevieve County Memorial Hospital
-
Springfield、Missouri、アメリカ、65804
- Mercy Hospital Springfield
-
St Louis、Missouri、アメリカ、63131
- Missouri Baptist Medical Center
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
St Louis、Missouri、アメリカ、63128
- Mercy Hospital South
-
Sullivan、Missouri、アメリカ、63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman、Montana、アメリカ、59715
- Bozeman Health Deaconess Hospital
-
-
New York
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Lake Success、New York、アメリカ、11042
- Northwell Health/Center for Advanced Medicine
-
New York、New York、アメリカ、10019
- Mount Sinai West
-
New York、New York、アメリカ、10029
- Mount Sinai Hospital
-
New York、New York、アメリカ、10011
- Mount Sinai Chelsea
-
New York、New York、アメリカ、10075
- Lenox Hill Hospital
-
New York、New York、アメリカ、10065
- Manhattan Eye Ear and Throat Hospital
-
Oswego、New York、アメリカ、13126
- Upstate Cancer Center at Oswego
-
Oswego、New York、アメリカ、13126
- Upstate Cancer Center Radiation Oncology at Oswego
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
Syracuse、New York、アメリカ、13215
- SUNY Upstate Medical Center-Community Campus
-
Syracuse、New York、アメリカ、13210
- Upstate Cancer Center at Hill Radiation Oncology
-
Verona、New York、アメリカ、13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
Raleigh、North Carolina、アメリカ、27609
- Duke Cancer Center Raleigh
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron、Ohio、アメリカ、44304
- Summa Health System - Akron Campus
-
-
Oklahoma
-
Lawton、Oklahoma、アメリカ、73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City、Oklahoma、アメリカ、73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham、Oregon、アメリカ、97030
- Legacy Mount Hood Medical Center
-
Portland、Oregon、アメリカ、97239
- Oregon Health and Science University
-
Portland、Oregon、アメリカ、97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin、Oregon、アメリカ、97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Chadds Ford、Pennsylvania、アメリカ、19317
- Christiana Care Health System-Concord Health Center
-
Danville、Pennsylvania、アメリカ、17822
- Geisinger Medical Center
-
Hershey、Pennsylvania、アメリカ、17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg、Pennsylvania、アメリカ、17837
- Geisinger Medical Oncology-Lewisburg
-
Reading、Pennsylvania、アメリカ、19605
- Penn State Health Saint Joseph Medical Center
-
Wilkes-Barre、Pennsylvania、アメリカ、18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
-
Texas
-
Amarillo、Texas、アメリカ、79106
- The Don and Sybil Harrington Cancer Center
-
-
Virginia
-
Richmond、Virginia、アメリカ、23235
- VCU Massey Cancer Center at Stony Point
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
Tappahannock、Virginia、アメリカ、22560
- VCU Health Tappahannock Hospital
-
-
Washington
-
Vancouver、Washington、アメリカ、98686
- Legacy Salmon Creek Hospital
-
Vancouver、Washington、アメリカ、98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
Walla Walla、Washington、アメリカ、99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Ashland、Wisconsin、アメリカ、54806
- Northwest Wisconsin Cancer Center
-
Eau Claire、Wisconsin、アメリカ、54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse、Wisconsin、アメリカ、54601
- Gundersen Lutheran Medical Center
-
La Crosse、Wisconsin、アメリカ、54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Minocqua、Wisconsin、アメリカ、54548
- Marshfield Medical Center - Minocqua
-
Mukwonago、Wisconsin、アメリカ、53149
- ProHealth D N Greenwald Center
-
New Richmond、Wisconsin、アメリカ、54017
- Cancer Center of Western Wisconsin
-
Oconomowoc、Wisconsin、アメリカ、53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake、Wisconsin、アメリカ、54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point、Wisconsin、アメリカ、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha、Wisconsin、アメリカ、53188
- UW Cancer Center at ProHealth Care
-
Weston、Wisconsin、アメリカ、54476
- Marshfield Medical Center - Weston
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
- PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
- For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
- Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
- No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
- No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
- No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
- >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
- No prior allogeneic tissue/solid organ transplant
- No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of non-infectious pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
- No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
- Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A (immunotherapy, +/- chemotherapy)
Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
他の名前:
Undergo blood sample collection
他の名前:
Given IV
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Undergo ECHO
他の名前:
Undergo PET
他の名前:
Given IV
他の名前:
Undergo tissue biopsy
他の名前:
|
|
実験的:Arm B (immunotherapy, +/- chemotherapy, radiation therapy)
Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
他の名前:
Undergo blood sample collection
他の名前:
Given IV
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Undergo ECHO
他の名前:
Undergo PET
他の名前:
Given IV
他の名前:
Undergo radiation therapy
他の名前:
Undergo tissue biopsy
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS) (Phase II)
時間枠:From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Will be performed on an intent-to-treat (ITT) basis. |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Overall survival (OS) (Phase III)
時間枠:From randomization and death of all causes, assessed up to 5 years
|
Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status. |
From randomization and death of all causes, assessed up to 5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
生活の質
時間枠:5年まで
|
5年まで
|
|
|
PFS
時間枠:From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Assessed per Response Evaluation Criteria in Solid Tumors (RECIST). |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Objective response rate (ORR)
時間枠:Up to 5 years
|
Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates. |
Up to 5 years
|
|
Incidence of treatment-related adverse events
時間枠:Up to 5 years
|
Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test. |
Up to 5 years
|
協力者と研究者
捜査官
- 主任研究者:Christine M Bestvina、Alliance for Clinical Trials in Oncology
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 気道疾患
- 組織型別の新生物
- 肺疾患
- 新生物、腺および上皮
- 腺癌
- 気道腫瘍
- 胸部腫瘍
- がん
- がん、気管支原性
- 気管支腫瘍
- 肺の腺癌
- 肺新生物
- がん、非小細胞肺
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 調査手法
- 治療
- 臨床検査技術
- 診断技術と手順
- 診断
- 外科的処置、手術
- 細胞学的技術
- 細胞診断
- 生物学的要因
- 物理現象
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 診断技術、外科的
- 化学技術、分析
- スペクトル分析
- 受容体、細胞表面
- 膜タンパク質
- 抗原
- 抗原、表面
- バイオマーカー
- 受容体、免疫学的
- 抗原、分化、Tリンパ球
- 抗原、分化
- 免疫チェックポイントタンパク質
- 共刺激および阻害性T細胞受容体
- ニボルマブ
- イピリムマブ
- 放射線療法
- 放射線
- 生検
- 標本処理
- 磁気共鳴分光法
- CTLA-4抗原
その他の研究ID番号
- NCI-2021-06042
- U10CA180821 (米国 NIH グラント/契約)
- NCI-2021-06042 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- A082002 (その他の識別子:CTEP)
- A082002 (その他の識別子:Alliance for Clinical Trials in Oncology)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。